Mitsubishi Tanabe Pharma Corporation

Type: Company
Name: Mitsubishi Tanabe Pharma Corporation
First reported 16 hours ago - Updated 8 hours ago - 1 reports

Vivus, Inc. Opens Sharply Higher On ED Drug Marketing Approval

Vivus Inc. (NASDAQ: VVUS) shares rose sharply in pre-market activity after its fast-acting erectile dysfunction drug won marketing approval Thursday from federal regulators.The drug, avanafil, can be effective when taken as early as 15 minutes before ... [Published Benzinga.com - 16 hours ago]
First reported 20 hours ago - Updated 20 hours ago - 1 reports

Vivus And Auxilium Pharma Say FDA Approves SNDA For Stendra - Quick Facts

Vivus Inc. (VVUS: Quote) and Auxilium Pharmaceuticals, Inc. (AUXL: Quote) announced that the U.S. Food and Drug Administration or FDA has approved a supplemental new drug application or sNDA for Stendra (avanafil).The companies said that STENDRA is now ... [Published RTTNews.com - 20 hours ago]
First reported Sep 11 2014 - Updated Sep 12 2014 - 1 reports

Novartis Presents Data on Multiple Sclerosis Drug Gilenya

Novartis ( NVS - Analyst Report ) presented encouraging data on multiple sclerosis (MS) drug, Gilenya, from a follow-up extension study, LONGTERMS, at the Joint ACTRIMS-ECTRIMS Meeting in Boston. Gilenya was seen to sustain its efficacy in treating ... [Published Zacks.com - Sep 11 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 1 reports

AstraZeneca to present diabetes drug data in Vienna

iNVEZZ.com, Wednesday, September 10: AstraZeneca Plc (LON:AZN) will present data for several diabetes drugs at an upcoming event in Vienna, the Anglo-Swedish drugmaker has said. The abstracts are expected to cover some of the company’s approved products ... [Published Invezz - Sep 10 2014]
First reported Sep 05 2014 - Updated Sep 05 2014 - 1 reports

AstraZeneca And Redx Ink R&D Deal On Tumor Genetics

By Estel Grace MasangkayBritish drug firm AstraZeneca and Redx Pharma announced that they have signed into a research collaboration to discover and develop new molecules that will combat a genetic driver of tumor survival and growth.As part of the agreement, ... [Published Bioresearch Online - Sep 05 2014]
First reported Sep 05 2014 - Updated Sep 05 2014 - 1 reports

AstraZeneca and MTPC announce research collaboration in diabetic nephropathy

AstraZeneca and Mitsubishi Tanabe Pharma Corporation, or MTPC, have announced three-year research collaboration in the area of diabetic nephropathy. The aim of the research collaboration is to leverage complementary strengths, expertise and assets to ... [Published Individual.com - Sep 05 2014]
First reported Sep 01 2014 - Updated Sep 01 2014 - 1 reports

Mitsubishi Chemical Holdings Shelf Reg.: R&I Assigns A

Rating and Investment Information, Inc. (R&I) has announced the following:Mitsubishi Chemical Holdings Corp. (MCHC) is the holding company of the MCHC Group, which develops a wide variety of businesses in the domains of performance products, health care ... [Published Noodls - Sep 01 2014]
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

Kyowa Hakko Kirin Announces Commencement of Phase 2b Clinical Study of KHK7580 in Patients with Secondary Hyperparathyroidism in Japan

--- Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151, President and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") today announced the initiation of a phase 2b clinical study evaluating KHK7580 for secondary hyperparathyroidism patients receiving hemodialysis in Jap ... [Published Noodls - Aug 29 2014]
First reported Aug 25 2014 - Updated Aug 26 2014 - 1 reports

Janssen Affiliate Cilag Acquires Covagen

Cilag International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, acquired Covagen , a biopharmaceutical company specializing in the development of multispecific protein therapeutics through its FynomAb® technology platform. ... [Published Genetic Engineering News - Aug 25 2014]
First reported Aug 20 2014 - Updated Aug 21 2014 - 2 reports

AstraZeneca and Mitsubishi Tanabe Pharma Collaborate in Diabetic Nephropathy

AstraZeneca and Mitsubishi Tanabe Pharma Corporation (MTPC) have entered a three-year research collaboration in the area of diabetic nephropathy (failure of the kidney function due to diabetes). The aim of the research collaboration is to validate and ... [Published PharmTech.com - Aug 20 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 2 reports

Astrazeneca And Mitsubishi Collaborate For Diabetes Research

AstraZeneca and Mitsubishi Tanabe have agreed to a three-year research collaboration on drugs for diabetic neuropathyPage 1 of 2Published: August 20, 2014 at 9:27 am EST By: Hannah Ishmael Click Ticker to See live coverage AZN MTZPYAstraZeneca plc ... [Published Bidness Etc - Aug 20 2014]
First reported Aug 11 2014 - Updated Aug 11 2014 - 3 reports

FDA approves combination type 2 diabetes pill from Janssen

Janssen Pharmaceuticals Inc, part of US Johnson& Johnson (NYSE:JNJ), said Friday that Invokamet, a fixed-dosecombination of canagliflozin and metformin hydrochloride in a singletablet, had been cleared by the US FDA to treat adults with Type 2diabete ... [Published MedCity News - Aug 11 2014]

Quotes

"Patients are looking for a safe and effective treatment that also works fast" lead investigator Wayne J G Hellstrom of Tulane School of Medicine said
"MTPC is now focusing its drug discovery research efforts and multifaceted translational research, including collaboration with Kyoto University Hospital and TMK project, to developing new treatments for chronic kidney disease patients. We expect the new collaboration with AstraZeneca will strengthen the expertise of both companies in this area and accelerate the delivery of new medicines for patients with diabetic nephropathy" said Takashi Kobayashi, Division manager of Research division, MTPC
...body weight and systolic blood pressure," said Jimmy Ren, Ph D , Therapeutic Area Lead, Metabolics, Medical Affairs, Janssen Pharmaceuticals, Inc. "The available doses of INVOKAMET allow physicians to tailor therapy for individual patient needs and offer an alternative for patients who may be able to reduce the number of tablets they take each day."
"Our interest in Covagen stems from the company's scientific acumen, their novel FynomAb platform, and the potential of COVA 322, a bispecific designed to achieve better control of inflammation by blocking two key cytokines that have been implicated in disease pathogenesis and progression,” said Susan B Dillon, Ph D , global therapeutic area head of immunology, Janssen Research & Development. “We look forward to progressing COVA 322 development, and to further expanding the potential of multispecific biologics for immunologic and other diseases.”"

More Content

All (25) | News (21) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (2) | Press Releases (0)
sort by: Date | Relevance
Vivus, Inc. Opens Sharply Higher On ED Drug Mar... [Published Yahoo! Finance - 14 hours ago]
Vivus, Inc. Opens Sharply Higher On ED Drug Mar... [Published Benzinga.com - 16 hours ago]
Vivus And Auxilium Pharma Say FDA Approves SNDA... [Published RTTNews.com - 20 hours ago]
Novartis Presents Data on Multiple Sclerosis Dr... [Published Zacks.com - Sep 11 2014]
AstraZeneca to present diabetes drug data in Vi... [Published Invezz - Sep 10 2014]
AstraZeneca And Redx Ink R&D Deal On Tumor Gene... [Published Bioresearch Online - Sep 05 2014]
AstraZeneca and MTPC announce research collabor... [Published Individual.com - Sep 05 2014]
Mitsubishi Chemical Holdings Shelf Reg.: R&I As... [Published Noodls - Sep 01 2014]
Dezima Reports Positive Results in its Phase 2b... [Published CEOWorld Magazine - Aug 29 2014]
Kyowa Hakko Kirin Announces Commencement of Pha... [Published Noodls - Aug 29 2014]
Janssen Pharmaceuticals receives FDA approval f... [Published Individual.com - Aug 25 2014]
Janssen Affiliate Cilag Acquires Covagen [Published Genetic Engineering News - Aug 25 2014]
AstraZeneca share price: Drugmaker unveils part... [Published Invezz - Aug 21 2014]
AstraZeneca and Mitsubishi Tanabe Pharma Collab... [Published PharmTech.com - Aug 20 2014]
Astrazeneca And Mitsubishi Collaborate For Diab... [Published Bidness Etc - Aug 20 2014]
AstraZeneca share price: Group inks diabetes re... [Published Invezz - Aug 20 2014]
AZ inks diabetic nephropathy pact with Mitsubis... [Published Pharma Times - Aug 20 2014]
AZ and Mitsubishi partner on diabetic nephropathy [Published Pharmafocus - Aug 20 2014]
FDA approves combination type 2 diabetes pill f... [Published MedCity News - Aug 11 2014]
FDA Approves INVOKAMETT for the Treatment of Ad... [Published PharmaceuticalProcessing - Aug 11 2014]
Invokamet approved in US to treat adults with t... [Published PharmaBiz - Aug 11 2014]
Surveyed U.S. Psychiatrists Would Prescribe EnV... [Published PR Newswire: General Business - Mar 31 2014]
Find Your Next Asia Partnership in Tokyo at BIO... [Published I Am Biotech - Mar 12 2014]
Fact Sheet for Mitsubishi Chemical Holdings Corp [Published Silobreaker - Feb 05 2010]
Fact Sheet for Mitsubishi Chemical Holdings Cor... [Published Able2Act - Dec 28 2007]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Surveyed U.S. Psychiatrists Would Prescribe EnV... [Published PR Newswire: General Business - Mar 31 2014]
BURLINGTON, Mass., March 31, 2014 /PRNewswire/ -- Decision Resources Group finds that surveyed U.S. psychiatrists would prescribe EnVivo Pharmaceuticals/Bayer HealthCare/Mitsubishi Tanabe Pharma's encenicline to 25 percent of their patients with cognitive ...
Find Your Next Asia Partnership in Tokyo at BIO... [Published I Am Biotech - Mar 12 2014]
On April 8-9, 2014, the  BIO Asia International Conference  will enter its eleventh year. This year, bioparma industry leaders will convene at the Grand Hyatt in Tokyo, Japan to make the cross border deals that will advance collaboration between Asia ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.